Epigenetic modifier gene mutations‐positive AML patients with intermediate‐risk karyotypes benefit from decitabine with CAG regimen
- 25 July 2019
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 146 (5) , 1457-1467
Abstract
It remains unclear whether there is a relationship between therapeutic effects of hypomethylating agents (HMAs) and epigenetic modifier gene mutations (EMMs) in patients with cytogenetically intermediate‐risk acute myeloid leukemia (IR‐AML). Based on targeted‐capture sequencing, we retrospectively analyzed the correlation between EMMs and prognosis in 83 IR‐AML patients treated with decitabine in combination with cytarabine, aclarubicin hydrochloride and granulocyte colony‐stimulating factor (DCAG, n = 35) or “7 + 3” induction regimens (n = 48). In the multivariate analyses, EMM (+) patients did not show any statistically significant difference in remission rates from EMM (−) patients in the DCAG group (p > 0.05), but achieved inferior complete remission (CR; p = 0.03) and overall remission rates (ORR; p = 0.04) after the first course of standard induction regimens (p < 0.05). In the EMM (−) cohort, the DCAG group showed the tendency of adverse total CR (p = 0.06). Besides, DCAG group with EMMs achieved the best survival outcome independent of baseline characteristics, whereas it was opposite in EMM (+) patients receiving standard induction regimens (p < 0.05). Additionally, in the EMM (+) cohort, the survival rate of isolated DCAG group was statistically similar to that of the combination of standard chemotherapies and allogeneic hematopoietic stem cell transplantation (allo‐HSCT) (p > 0.40), whereas patients who received only standard regimens had the worst survival rate (0.0%, p < 0.01). It can be concluded that the EMMs might be regarded as the potentially predictive biomarkers of better response to DCAG in IR‐AML patients.Keywords
Funding Information
- National Natural Science Foundation of China (81170518, 81370635, 81470010, 81570137, 81670162, 81800135, 81870134)
This publication has 23 references indexed in Scilit:
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013
- Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemiaLeukemia & Lymphoma, 2013
- Gene mutations of acute myeloid leukemia in the genome eraInternational Journal of Hematology, 2013
- ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcomeLeukemia, 2012
- DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemiaLeukemia, 2011
- DNMT3AMutations in Acute Myeloid LeukemiaNew England Journal of Medicine, 2010
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProceedings of the National Academy of Sciences, 2010
- Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell LinesClinical Cancer Research, 2007
- Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal KaryotypeNew England Journal of Medicine, 2005